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Summary
In the Medical Research Council (MRC) Myeloma IX trial (ISRCTN684564111)
patients were randomised to sodium clodronate or zoledronic acid and induc-
tion treatment: cyclophosphamide, vincristine, doxorubicin and dexamethasone
(CVAD) or cyclophosphamide, thalidomide and dexamethasone (CTD) fol-
lowed by autologous stem cell transplant (ASCT) in the intensive pathway;
attenuated CTD or melphalan and prednisolone (MP) in the non-intensive
pathway. Subsequent randomisation allocated patients to either thalidomide or
observation. The European Organisation for Research and Treatment of Cancer
(EORTC) quality of life (QoL) questionnaires, QLQ-C30 and QLQ-MY24, were
administered at baseline, 3, 6 and 12 months and annually thereafter, enabling
the effect of sequential treatment on patient-reported health-related QoL (HR-
QoL) to be investigated. The protocol specified four subscales of interest: Pain,
Fatigue, Global Health Status/Quality of Life and Physical Functioning at 3, 6
and 12 months that were compared using linear models. The intensive pathway
showed significant differences in favour of CTD for Fatigue at 3 months and
Physical Functioning at 12 months. The non-intensive pathway and mainte-
nance phase reported significant differences at 3 months; Pain (improved with
attenuated CTD) and Global Health status/Quality of Life (improved with
observation). The improved outcomes in MRC Myeloma IX were accompanied
by some beneficial and few detrimental effects on HR-QoL.
Keywords: multiple myeloma, quality of life, EORTC QLQ-C30, EORTC
MY-24, immunomodulatory agent.
The widespread adoption of intensive therapy and the subse-
quent introduction of novel agents in the treatment of multi-
ple myeloma (MM) inevitably raises questions as to effects
on health-related quality of life (HR-QoL). However, there is
still relatively little published quality of life (QoL) data in
systematically treated and assessed patients, notably in the
first-line treatment setting.
The Medical Research Council (MRC) series of ran-
domised controlled trials of treatment in previously
untreated patients with MM up to MRC Myeloma IX pro-
vided only limited data on performance status. Myeloma IX
included intensive and non-intensive pathways and enrolled
patients of all ages. Patient-reported HR-QoL was a sec-
ondary endpoint in the trial protocol, with the aim of
obtaining QoL data during the induction, consolidation and
maintenance phases of treatment to assess the impact of the
different regimens and components of treatment. Here, we
present the results of the longitudinal analyses.
Methods
MRC myeloma IX
Myeloma IX recruited patients with newly-diagnosed MM
aged ≥18 years from 120 centres in the United Kingdom
between 2003 and 2007 and was registered with the appro-
priate organisation (ISRCTN68454111). All 120 centres
reviewed the protocol and all recruited participants gave
written informed consent in accordance with the Declaration
of Helsinki, with an opt-in component for the QoL sub-
study. The study was an open-label randomised, phase III
trial with a factorial design in which there were two
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randomisations. The first included randomised allocation of
patients to receive a bisphosphonate (sodium clodronate or
zoledronic acid) and induction treatment, either intensive or
non-intensive, determined by the treating clinicians’ assess-
ments in combination with patient performance status and
preferences following informed discussion. In the intensive
pathway, patients were randomised to receive cyclophos-
phamide, vincristine, doxorubicin and dexamethasone
(CVAD) or oral cyclophosphamide, thalidomide and dexam-
ethasone (CTD) followed by high dose melphalan plus autol-
ogous stem cell transplant (ASCT). In the non-intensive
pathway, the randomisation was to attenuated CTD (CTDa)
or melphalan and prednisolone (MP). A further randomisa-
tion allocated patients to either thalidomide maintenance
therapy or observation only. Details of the trial, including
the randomisation methods and sample size calculation, have
been published elsewhere together with results of primary
and secondary endpoints related to treatment effectiveness
and safety (Morgan et al, 2010, 2012a,b,c, 2013).
Patient-reported outcome data collection
To collect patient-reported QoL information, two patient-
completed European Organisation for Research and Treatment
of Cancer (EORTC) questionnaires were used: the EORTC
QLQ-C30 and QLQ-MY24. The QLQ-C30 is a fully validated
tool used for assessing the QoL of cancer patients (Aaronson
et al, 1993). When scored, the 30 questions produce 15 sub-
scales relating to HR-QoL. The QLQ-MY24 is a specific ques-
tionnaire module for patients with MM (Stead et al, 1999).
The QLQ-MY24 was validated throughout the original study
period and consists of 24 questions, which when scored results
in 5 subscales. As a result of the validation process the QLQ-
MY24 has been refined to the QLQ-MY20 (removing the
Social Support subscale) (Cocks et al, 2007). However, as it
was administered, the original QLQ-MY24 is used here.
The over-arching QoL population was defined as any
patient in the intention to treat (ITT) population, who
returned a questionnaire at any time point. The protocol sta-
ted that consenting patients should complete questionnaires
at baseline, 3, 6, 12 months and then annually up to 5 years
post-randomisation, unless the patient participated in the
maintenance randomisation when they should complete a
pre-maintenance randomisation questionnaire and then at
the same intervals as above. For the primary analysis three
separate QoL populations were considered; intensive, non-
intensive and maintenance. The intensive population was
defined as any individual who returned a questionnaire dur-
ing their induction treatment (pre-second randomisation)
and was randomised to receive CTD or CVAD. Similarly, the
non-intensive population was defined as any individual who
returned a questionnaire during their induction treatment
(pre-second randomisation) and was randomised to receive
CTDa or MP. Finally, the maintenance population was
defined as any individual who was randomised to receive
maintenance therapy (thalidomide or observation only) and
returned a questionnaire during their treatment. In all three
populations, questionnaire compliance was calculated as the
proportion of those in the population who returned a ques-
tionnaire out of those expected to return a questionnaire
(alive on study treatment and not withdrawn). An alternative
population to the non-intensive and intensive populations
was defined for some of the exploratory analysis. This con-
sidered the two populations together as a first randomisation
population; specifically, any individual who returned a ques-
tionnaire during their induction treatment (pre-second ran-
domisation) was included in this population.
Data imputation and subscale scoring
Missing questionnaire data and relevant baseline factors were
imputed using multiple imputation by chained equations
(MICE) (White et al, 2011). The imputation was conducted
separately for the three analysis populations described above.
In addition, the imputation was conducted by randomised
induction treatment in the intensive and non-intensive path-
ways and randomised treatment in the maintenance phase,
therefore only individuals with the same randomisation allo-
cation contributed to an individual’s imputed value.
The total number of imputed datasets was determined as
the maximum percentage of ‘missingness’ in a compulsory
question at any time point, or baseline measurement [stratifi-
cation factors, age, sex and International Staging System
(ISS)] across the three populations. For each population,
imputation was conducted in temporal order, therefore the
baseline measurements were imputed first, followed by base-
line questionnaire values, then the 3 months questionnaire
values and so on. Within each time point, the variables were
imputed in order of least to most missing. Note that only
questionnaires from the treatment period being considered
were used within each imputation phase: for example, only
induction questionnaires from non-intensive pathway
patients were used to impute data for the non-intensive
pathway.
The imputed datasets were scored according to the ques-
tionnaire manuals and analysis performed in each imputed
dataset. The parameter estimates (coefficient and standard
errors) were combined according to Rubin (1987) and
appropriate Wald tests obtained (White et al, 2011). All anal-
yses was undertaken using SAS version 9.4 (SAS Institute,
Cary, NC, USA) and data collected up to 8 May 2014.
Primary analysis
Analyses of patient-reported QoL were pre-specified in a sepa-
rate statistical analysis plan. For the primary analysis the depen-
dent variables were defined as the four subscales of interest
(Pain, Fatigue, Global Health Status/Quality of Life and Physical
Functioning) at three time points (3, 6 and 12 months) for each
analysis population (intensive, non-intensive and maintenance).
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Multiple linear regression was used to regress the subscale
of interest at each time point on the variable of interest. For
the first randomisation, this was the allocated induction treat-
ment (intensive: CTD versus CVAD, non-intensive: CTDa ver-
sus MP) adjusting for the baseline value of the subscale, the
bisphosphonate allocation (sodium clodronate or zoledronic
acid), ISS (I-III), age, sex, haemoglobin at baseline (<115,
≥115 g/l for males; <95, ≥95 g/l for females), corrected serum
calcium at baseline (<26, ≥26 mmol/l), serum creatinine at
baseline (<140, ≥140 lmol/l) and platelet count at baseline
(<150, ≥150 9 109/l). Similarly, for the maintenance randomi-
sation, the variable of interest was the randomised treatment
allocation (thalidomide versus observation only) adjusting for
the baseline value of the subscale, the treatment group allo-
cated by the first randomisation, ISS (I–III), age and sex. The
assumptions of the linear regression models were investigated
for each comparison. All statistical tests were two-sided and
assessed at the 5% level of significance. As a guide for interpre-
tation, an arbitrary difference of ≥10 points in a subscale was
pre-defined as the minimal important difference (MID)
required to suggest clinical relevance (Osoba et al, 1998).
Sensitivity and exploratory analysis
Sensitivity analysis assessed the impact of imputation by esti-
mating models on complete case information. Exploratory
analysis consisted of graphical displays, which summarized all
questionnaire subscales with respect to the induction treat-
ments and bisphosphonate using complete case information.
Results
Patient progress and baseline characteristics
Overall 1970 patients were recruited to Myeloma IX; 1822
(9249%) of these were included in the QoL sub-study. The
progress of patients through the sub-study is shown for the
1819 participants at first randomisation (N = 1061 intensive
pathway, N = 758 non-intensive pathway) and for the 751
patients at maintenance randomisation in the CONSORT dia-
grams (Fig 1). In each population intensive and non-intensive
pathways [Table I (key demographics and subscales of special
interest), Table SI (haematological characteristics and remain-
ing subscales)] and maintenance phase (Table SII) the distri-
butions of age, gender, ISS and baseline QoL were similar by
allocated treatment. The average ages of patients in the inten-
sive pathway, non-intensive pathway and maintenance phase
were 58, 73 and 63 years respectively, the latter figure reflect-
ing the inclusion of patients from the two pathways.
Questionnaire return
The CONSORT diagrams show the questionnaire return rate
by allocated treatment group (Fig 1). The return rate and
completeness of the questionnaires were generally good with
a lower return rate at baseline (20% missing baseline ques-
tionnaires in both the intensive and non-intensive pathways
and 44% missing in the maintenance phase). In the intensive
pathway, the CVAD group had a fairly constant rate of
‘missingness’, which contrasted with the CTD group where a
large discrepancy was observed at 4 years (CVAD: 16% miss-
ing, CTD: 24% missing). In the non-intensive pathway, a
similar proportion of questionnaires were returned in both
groups at each time point with the exception of 12 months
post-randomisation (MP: 13% missing, CTDa: 24% missing).
In the maintenance phase, the return rate improved after the
low return rate at baseline, with only approximately 10% of
questionnaires missing up to 3 years post-randomisation.
The highest percentage of total ‘missingness’ not relating to a
conditional question was 63%, 71% and 48% for the inten-
sive and non-intensive pathways and maintenance phase,
respectively. Thus 71 imputed datasets were created for each
analysis population.
Principal findings in the treatment pathways
In the intensive pathway there were no significant differences
at any time point between treatment with CVAD and CTD
with respect to Pain and Global Health Status/Quality of Life
(Fig 2A). However, there were small significant differences in
favour of CTD for Fatigue at 3 months with a persistent trend
for benefit at 6 and 12 months (Fatigue lower with CTD,
3 months: 402 [95% confidence interval (CI) 743,
061], P = 002; 6 months: 206 [95% CI 672, 448],
P = 039; 12 months: 363 [95% CI 851, 126], P = 015,
Fig 2A) and Physical Functioning at 12 months after small
non-significant benefits at 3 and 6 months (Physical Function-
ing higher with CTD, 3 months: 083 [95% CI 237, 404],
P = 061; 6 months: 082 [95% CI 247, 410], P = 063;
12 months: 449 [95% CI 022, 876], P = 004, Fig 2A).
In the non-intensive pathway there was a small but highly
significant difference in favour of CTDa for Pain at 3 months
with a persistent trend for benefit at 6 and 12 months (Pain
lower for CTDa, 3 months: 888 [95% CI 1358, 418],
P = 00002; 6 months: 482 [95% CI 991, 026],
P = 006; 12 months: 457 [95% CI 1196, 281],
P = 022, Fig 2B). This difference was smaller than our pre-
specified MID. There were no significant differences for Fati-
gue, Global Health Status/Quality of Life or Physical Func-
tioning (Fig 2B).
In the maintenance phase there was a small significant dif-
ference in favour of observation only for Global Health Sta-
tus/Quality of Life at 3 months with a persistent trend for
detriment at 6 months and 12 months (Global Health Sta-
tus/Quality of Life lower with thalidomide maintenance,
3 months: 339 [95% CI 633, 045], P = 002;
6 months: 128 [95% CI 486, 230], P = 048;
12 months: 215 [95% CI 598, 167], P = 027, Fig 2C).
There were no significant differences for Pain, Fatigue or
Physical Functioning (Fig 2C).
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Intensive pathway
Quality of life
1054 gave QoL consent 
22 gave implicit QoL consent
35 refused QoL consent
520 assigned to CVAD 541 assigned to CTD
3 months
6 months
12 months
2 years
3 years
Baseline
4 years
5 years
24 died
29 died
1 withdrew
19 moved to maintenance therapy
18 died
11 moved to maintenance therapy
13 died
19 died
20 died
27 died
37 moved to maintenance therapy
35 died
1 withdrew
28 died
18 died
17 moved to maintenance therapy
21 died
182 moved to maintenance therapy
22 died
1 withdrew
211 moved to maintenance therapy
21 died
19 died
-
278 assigned to receive 
clodronic acid plus CVAD 
277 assigned to receive 
zoledronic acid plus CTD
278 assigned to receive 
clodronic acid plus CTD
278 assigned to receive 
zoledronic acid plus CVAD
1111 eligible for ITT analysis
3 excluded 
1 no consent received
1 misdiagnosed
540 started CVAD
16 did not start CVAD
4 died prior to treatment
8 other
4 missing reason
747 received 200 mg/m2 melphalan and autologous stem-
383 on zoledronic acid
364 on clodronic acid
364 did not receive high-dose melphalan plus autologous stem-
93 died 
15 inadequate number of stem cells
98 other
548 started CTD
7 did not start CTD
6 other
1 missing reason
(A)
Fig 1. CONSORT diagrams. For the intensive pathway (A), non-intensive pathway (B) and the maintenance phase (C). CTD, cyclophosphamide,
thalidomide and dexamethasone; CTDa, attenuated cyclophosphamide, thalidomide and dexamethasone; CVAD, cyclophosphamide, vincristine,
doxorubicin and dexamethasone; ITT, intention to treat; MP, melphalan and prednisolone; QoL, quality of life.
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Fig 1b. (Continued)
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Maintenance phase
820 randomised to maintenance treatment 
255 on zoledronic acid (intensive pathway)
238 on clodronic acid (intensive pathway)
175 on zoledronic acid (non-intensive pathway)
152 on clodronic acid (non-intensive pathway)
818 eligible for ITT analysis
408 assigned to receive thalidomide
184 started thalidomide
5 did not start thalidomide
3 other
2 missing reason
6 missing data 
193 started thalidomide
13 did not start thalidomide
12 other
1 died
7 missing data 
190 did not start thalidomide
3 started thalidomide
2 missing data
212 did not start thalidomide
1 started thalidomide
2 missing data
Quality of life
Baseline
3 Months
4 Years
3 Years
2 Years
12 Months
6 Months
5 Years
2 excluded
1 no consent received
1 withdrew consent
761 gave QoL consent 
14 gave implicit QoL consent
43 refused QoL consent
381 assigned to receive thalidomide
3 died
21 died
47 died
37 died
38 died
34 died
3 died
16 died
33 died
37 died
37 died
9 died 10 died
40 died
1 withdrew
(C)
Fig 1c. (Continued)
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There was no indication of strong violations of the mod-
elling assumptions. Any observed violations were consistent
within each imputed dataset as well as in the complete case
analysis.
Long-term QoL in subscales of special interest
In the longer-term, at 2, 3, 4 and 5 years post-randomisa-
tion, the pre-specified subscales of Pain, Fatigue, Global
Health Status/Quality of Life and Physical Functioning show
few differences between the allocated treatments in the inten-
sive pathway, non-intensive pathway or maintenance phase.
In the intensive pathway (Fig 3A) there is a relatively short-
term negative effect on both Fatigue and Physical Function-
ing that could be attributable to high-dose therapy and
ASCT. However, these negative effects do not persist beyond
1 year of follow-up and do not translate to Global Health
Status/Quality of Life, which has a general increasing trend,
or to any of the other subscales. There are no clear temporal
trends in the subscales of special interest for either the non-
intensive pathway or maintenance phase (Fig 3B and C
respectively).
Short and long-term QoL in other subscales
Other EORTC QLQ-C30 and QLQ-MY24 subscales show lar-
gely similar trends and trajectories by allocated treatment. In
the intensive pathway CVAD patients had worse Diarrhoea,
Insomnia and Side Effects compared to CTD patients at
3 months. It appeared that patients in the CTD group had
worse Constipation than patients on CVAD at 3 months (Fig-
ure S1A). In the non-intensive pathway, patients on CTDa
had worse Constipation than patients on MP at 3 months
(Figure S1B). In the maintenance phase, Constipation was
worse in those on thalidomide maintenance therapy compared
to observation only both at 3 and 6 months (Figure S1C).
Table I. Select baseline demographics of the QoL population for patients in the intensive and non-intensive pathway. The full haematological
characteristics and remaining subscales can be found within Table SI.
Intensive pathway Non-intensive pathway
CVAD (n = 520) CTD (n = 541) Total (n = 1061) MP (n = 373) CTDa (n = 385) Total (n = 758)
Age (years) at first
randomisation,
mean (SD)
577 (739) 579 (747) 578 (743) 733 (574) 731 (500) 732 (537)
Sex, n (%)
Male 324 (623%) 336 (621%) 660 (622%) 204 (547%) 217 (564%) 421 (555%)
Female 196 (377%) 205 (379%) 401 (378%) 169 (453%) 168 (436%) 337 (445%)
Race, n (%)
Caucasian 510 (981%) 514 (950%) 1024 (965%) 365 (979%) 373 (969%) 738 (974%)
Black African 2 (04%) 7 (13%) 9 (08%) 1 (03%) 2 (05%) 3 (04%)
Black Caribbean 2 (04%) 3 (06%) 5 (05%) 4 (11%) 3 (08%) 7 (09%)
Asian 4 (08%) 9 (17%) 13 (12%) 1 (03%) 1 (03%) 2 (03%)
Other 1 (02%) 7 (13%) 8 (08%) 1 (03%) 3 (08%) 4 (05%)
Missing data 1 (02%) 1 (02%) 2 (02%) 1 (03%) 3 (08%) 4 (05%)
ISS, n (%)
I 122 (235%) 150 (277%) 272 (256%) 63 (169%) 43 (112%) 106 (140%)
II 177 (340%) 185 (342%) 362 (341%) 139 (373%) 146 (379%) 285 (376%)
III 166 (319%) 157 (290%) 323 (304%) 141 (378%) 145 (377%) 286 (377%)
Missing data 55 (106%) 49 (91%) 104 (98%) 30 (80%) 51 (132%) 81 (107%)
Pain
Mean (SD) 533 (3441) 536 (3560) 534 (3501) 523 (3446) 500 (3576) 512 (3510)
Missing 118 112 230 74 89 163
Fatigue
Mean (SD) 502 (2936) 502 (2936) 502 (2936) 501 (2791) 500 (2988) 501 (2889)
Missing 118 112 230 78 88 166
Physical Functioning
Mean (SD) 615 (3007) 596 (3104) 605 (3057) 565 (2772) 581 (2934) 573 (2853)
Missing 117 112 229 76 89 165
Global Health Status /Quality of Life
Mean (SD) 512 (2758) 486 (2748) 499 (2754) 497 (2449) 516 (2710) 506 (2582)
Missing 118 117 235 79 94 173
CTD, cyclophosphamide, thalidomide and dexamethasone; CTDa, attenuated cyclophosphamide, thalidomide and dexamethasone; CVAD, cyclophos-
phamide, vincristine, doxorubicin and dexamethasone; MP, melphalan and prednisolone; SD, standard deviation; ISS, international staging system.
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Primary Analysis Results: Intensive Pathway 
 CTD vs CVAD
Subscale of interest
Pain at 3 months
Pain at 6 months
Pain at 12 months
Fatigue at 3 months
Fatigue at 6 months
Fatigue at 12 months
GHS/QoL at 3 months
GHS/QoL at 6 months
GHS/QoL at 12 months
Physical functioning at 3 months
Physical functioning at 6 months
Physical functioning at 12 months
Estimate
0·35
0·01
−2·31
−4·02
−2·06
−3·63
1·03
2·97
3·21
0·83
0·82
4·49
Confidence interval
−3·59  to  4·29
−4·47  to  4·48
−8·34  to  3·72
−7·43  to  −0·61
−6·72  to  2·60
−8·51  to  1·26
−1·66  to  3·71
−2·47  to  8·40
−2·81  to  9·23
−2·37  to  4·04
−2·47  to  4·10
0·22  to  8·76
P
0·86
1
0·45
0·02
0·39
0·15
0·45
0·28
0·29
0·61
0·63
0·04
−10 0 10
 CTD Lower← → CTD Higher
Primary Analysis Results: Non−Intensive Pathway 
 CTDa vs MP
Subscale of interest
Pain at 3 months
Pain at 6 months
Pain at 12 months
Fatigue at 3 months
Fatigue at 6 months
Fatigue at 12 months
GHS/QoL at 3 months
GHS/QoL at 6 months
GHS/QoL at 12 months
Physical functioning at 3 months
Physical functioning at 6 months
Physical functioning at 12 months
Estimate
−8·88
−4·82
−4·57
2·79
−0·47
−2·62
−3·30
1·06
1·79
−1·78
−0·31
0·84
Confidence interval
−13·58  to  −4·18
−9·91  to  0·26
−11·96  to  2·81
−1·25  to  6·84
−4·89  to  3·95
−8·62  to  3·69
−7·84  to  1·24
−3·78  to  5·90
−4·95  to  8·53
−5·66  to  2·10
−4·27  to  3·66
−4·69  to  6·37
P
<0·01
0·06
0·22
0·18
0·83
0·39
0·15
0·67
0·60
0·37
0·88
0·77
−10 0 10
                      CTDa Lower← → CTDa Higher
(A)
(B)
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Short and long-term QoL with respect to allocated
bisphosphonate treatment
There was no clear evidence of a difference in any subscale
with respect to allocated bisphosphonate treatment, as all of
the confidence intervals overlapped at each time point within
each subscale (Figure S2).
Discussion
The Myeloma IX study evaluated the use of an
immunomodulatory agent (as both induction and mainte-
nance treatment), zoledronic acid (a newer bisphosphonate
agent that required parenteral treatment) and high dose ther-
apy with ASCT (without entry criteria explicitly connected
to patient age) and showed a number of positive clinical out-
comes with improved overall response, progression-free
survival (PFS) and overall survival (OS). The analysis in this
report has shown that these improvements have not come at
the cost of clinically relevant decreases in patient-reported
HR-QoL over the short-term (during initial treatment) or in
the long-term (during maintenance treatment and subse-
quent follow-up).
For the primary analysis, the only factor to demonstrate a
clear and highly statistically significant difference between
treatments was the Pain result at 3 months, in favour of
CTDa (P = 00002), this result being supported by a persis-
tent trend in benefit at 6 and 12 months. Although there
were statistically significant differences at the 5% level in
Fatigue at 3 months and Physical Functioning at 12 months,
in favour of CTD, and in Global Health Status/Quality of
Life at 3 months in the maintenance phase in favour of
observation only compared with thalidomide maintenance,
Fig 2. Forest plots of the primary analysis results. For the intensive pathway (A) and non-intensive pathway (B) the models were adjusted for the base-
line value of the subscale, the bisphosphonate allocation, International Staging System (ISS), age, sex and the stratification factors of the first randomisa-
tion. For the maintenance phase (C), the models were adjusted for the baseline value of the subscale, the treatment group allocated by the first
randomisation, ISS, age and sex. Note that Pain and Fatigue are worse with higher scores whereas Global Health Status/Quality of Life and Physical Func-
tioning are better with higher scores. The black squares and horizontal lines represent the treatment estimate and the associated 95% confidence interval,
respectively. CTD, cyclophosphamide, thalidomide and dexamethasone; CTDa, attenuated cyclophosphamide, thalidomide and dexamethasone; CVAD,
cyclophosphamide, vincristine, doxorubicin and dexamethasone; GHS/QoL, Global Health Status/Quality of Life; MP, melphalan and prednisolone.
Primary Analysis Results: Maintenance Phase 
 Thalidomide vs Observation
Subscale of interest
Pain at 3 months
Pain at 6 months
Pain at 12 months
Fatigue at 3 months
Fatigue at 6 months
Fatigue at 12 months
GHS/QoL at 3 months
GHS/QoL at 6 months
GHS/QoL at 12 months
Physical functioning at 3 months
Physical functioning at 6 months
Physical functioning at 12 months
Estimate
−0·33
0·94
−2·24
2·61
1·40
−0·27
−3·39
−1·28
−2·15
−0·53
0·37
−0·27
Confidence interval
−4·58  to  3·92
−3·72  to  5·61
−6·71  to  2·23
−0·88  to  6·10
−2·14  to  4·94
−4·08  to  3·53
−6·33  to  −0·45
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these differences were all slight, and should be interpreted
with caution given the number of tests performed.
It is interesting that pain was reduced with CTDa com-
pared with MP, especially in the short term. It is apparent
that the treatment that is more active against the myeloma is
also the most effective at relieving pain, despite potentially
having greater toxicity. Although the therapies used in Mye-
loma IX have been largely superseded by more active agents,
this finding is still highly relevant to current studies, and is
important to explain to the patient, given that, although they
are receiving potentially more toxic drugs, the greater activity
of these drugs will render them more effective, both in terms
of treating the myeloma itself, but also potentially in terms
of relieving pain. The same applies to the other HR-QoL
measures, namely fatigue and physical functioning, which
appeared to be improved with CTD/CTDa.
In terms of clinical relevance, according to the pre-defined
MID, the primary analysis showed no ‘clinically relevant’
differences. However, adopting alternative guidance on the
interpretation of the individual elements of the EORTC
QLQ-C30 questionnaire suggests that all but Pain at
3 months, which favoured CTDa in the non-intensive path-
way, was unlikely to have much clinical relevance (Cocks
et al, 2011). This same interpretation would have been the
conclusion had we adopted alternative criteria where any-
thing between a 6- and 17-point difference in any sub-scale
is regarded as clinically relevant (Kvam et al, 2010).
However, if these results are considered temporally and in
the long-term, most of the subscales are in favour of the
experimental treatment. For example, Global Health Status/
Quality of Life in the intensive pathway increases in favour
of CTD as time passes, despite the difference not attaining
statistical or clinical significance according to our pre-deter-
mined MID. This raises the question, what is more impor-
tant: a large change in an individual scale, or multiple small
changes across key subscales that are maintained over time?
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Fig 3. Descriptive plots for the exploratory analysis showing the subscales; Pain, Fatigue, Global Health Status/Quality of Life and Physical Func-
tioning. For the intensive pathway (A), non-intensive pathway (B) and maintenance phase (C). These graphs present the mean subscale scores
and approximate 95% confidence intervals at each time point by the variable of interest for the four key subscales in complete case data. Note
that Pain and Fatigue are worse with higher scores whereas Global Health Status/Quality of Life and Physical Functioning are better with higher
scores. CTD, cyclophosphamide, thalidomide and dexamethasone; CTDa, attenuated cyclophosphamide, thalidomide and dexamethasone; CVAD,
cyclophosphamide, vincristine, doxorubicin and dexamethasone; MP, melphalan and prednisolone.
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Alternative definitions of a MID, whether it be ≥5 points
(Kvam et al, 2010; Verelst et al, 2011; Delforge et al, 2012),
subscale specific (Cocks et al, 2011; Dimopoulos et al, 2014;
Delforge et al, 2015), or ≥10 points, as used in this work,
makes comparison between studies very difficult and research
less meaningful. A consensus on such measurements is
clearly required.
In our study, absence of significant differences at each
time point during follow up indicates that there is little per-
turbation of HR-QoL in the intensive pathway, when com-
paring the influence of CTD and CVAD, in the non-
intensive pathway, when investigating the difference between
CTDa and MP, or in the maintenance phase when examining
the impact of thalidomide maintenance therapy compared to
observation only. Also, so far as the two bisphosphonates are
concerned, the informal comparisons suggest little difference
in HR-QoL between patients taking clodronate and those
receiving zoledronic acid.
These results are reassuring and supportive of our conclu-
sions concerning the improved responses and survival out-
comes following treatment in Myeloma IX. In the intensive
pathway, CTD improved the overall response rate compared
to CVAD and CTD was shown to be non-inferior to CVAD
in terms of PFS and OS (Morgan et al, 2012a). In the non-
intensive pathway, CTDa improved response rate over MP
and CTDa was shown to significantly improve PFS compared
to MP (Morgan et al, 2011). In the maintenance phase,
thalidomide was shown to improve PFS and was associated
with improved OS compared to observation only although
the median duration of maintenance therapy was only
9 months (Morgan et al, 2012c). Zoledronic acid reduced
the risk of skeletal-related events (Morgan et al, 2012b) and
significantly improved OS compared to sodium clodronate
(Morgan et al, 2010). These gains in response and outcome
were accompanied by some improvements rather than
impairment of QoL, as determined by current HR-QoL mea-
surement. However, the trial setting and the relatively short
periods of maintenance thalidomide delivered, median treat-
ment duration was 7 months (range, 0–50 months) overall
and 9 (range, 0–50 months) and 6 (range, 0–46 months)
months in the intensive and non-intensive pathways, respec-
tively (Morgan et al, 2012c), preclude any firm conclusions
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about the longer term impact of cumulative neuropathic and
other side effects on HR-QoL.
These findings are broadly similar to the few published
reports of comparable approaches to treatment. The VISTA
trial (Delforge et al, 2012) reported that QoL was compara-
ble between the two arms (bortezomib and MP (VMP) versus
MP) after approximately 1 year in a population similar to
the non-intensive pathway. The finding that thalidomide
maintenance therapy has little impact on QoL is consistent
with an earlier study (Verelst et al, 2011) and the combina-
tion of lenalidomide and low-dose dexamethasone (RD) ver-
sus MPT has been reported to improve OS without having a
negative effect to QoL (Delforge et al, 2015).
A limitation on all HR-QoL studies has been the high pro-
portion of missing data. Although the returned questionnaires
were largely complete, there was a substantial number of
questionnaires missing at each time point, the baseline ques-
tionnaire having the worst return rate. To avoid the exclusion
of a large proportion of patient data at later time points,
MICE was implemented to impute any missing question
answers or baseline measurements. MICE was chosen as it is a
suitable stochastic method which is easy to implement
(https://stats.idre.ucla.edu/sas/seminars/multiple-imputation-
in-sas/mi_new_1/), and has been applied in a number of
recent clinical trials (Ali et al, 2013; Coates et al, 2015; Neop-
tolemos et al, 2017). MICE assumes that the missing data are
missing at random (MAR). i.e., the data is missing condi-
tional on the information that is observed. MAR is an untest-
able assumption; however, it was thought to be acceptable as
the questionnaires were administered at definitive (randomi-
sation-based) rather than subjective (treatment- or disease-
based) time points. In addition, sensitivity analyses also
showed that results obtained using MICE were consistent with
those obtained in a complete case analysis. An alternative crit-
icism could be the choice to exclude any corrections for mul-
tiplicity. As only a subset of the total number of endpoints (4
out of 20) and time points (3 out of 7) were pre-specified and
modelled as of primary interest (generating 36 out of a possi-
ble 1020 tests) it was deemed not necessary. However, had we
adjusted for the 36 simultaneous tests the results and conclu-
sions would not have deviated from those discussed here
given the small number of statistically significant results.
Patient-reported HR-QoL has been considered an impor-
tant endpoint for patients with MM (Kvam & Waage, 2015),
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giving the patient input on the effects of treatment (Delforge
et al, 2012). The results of this study showed that improve-
ments in clinical outcomes were not at the detriment of
patient reported HR-QoL. The findings are reassuring in the
context of continuing development of sequential treatment
for induction, consolidation and maintenance. However,
such large-scale studies, this being the largest to date, are a
major undertaking and very unlikely to be given priority in
future studies. Indeed, it could be that more sensitive QoL
instruments, or potentially instruments focussed on specific
domains, for example neurological, will be required to iden-
tify clinically relevant differences between treatment combi-
nations. In the context of current trends in treatment with
combinations of immunomodulatory agents, proteasome
inhibitors, monoclonal antibodies and HDAC inhibitors, be
it in modules of intensification as consolidation intended to
achieve MRD negativity, sequential, multi-agent treatment as
longer term “maintenance”, or both, there will be a need to
monitor the impact on patients’ QoL. New standardised, ide-
ally simplified, approaches that consider specific side effects
of given agents as well as key QoL measures should be
explored.
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